Fundamental and Clnical Evaluation of “Combipenix”(AB-PC·MDI-PC Combination)in the Otorhinolaryngologic Field

• Published in: jibi to rinsho Vol. 24; no. 3; pp. 386 - 395
• Main Authors: SHIMIZU, Yusuke, FUJITANI, Tetsuzo, NAKAGAWA, Iwao, TANIGUCHI, Satomi, INOGUCHI, Jun, TORIYAMA, Kazukiyo, OGINO, Kozo, OKA, Akikuni, KOKAN, Tsugio
• Format: Journal Article
• Language: Japanese
• Published: JIBI TO RINSHO KAI 20.05.1978
• ISSN: 0447-7227; 2185-1034
• DOI: 10.11334/jibi1954.24.3_386

Fundamental and clinical studies on “Combipenix” were performed with the results of following conclusions. 1. Using SD strain rats, the basic preliminary experiments showed no change of antimicrobial activity of the drug either in muscle homoginate or in blood within 10 days at -20° in a deep freezer. 2. Blood levels of the drug in healthy adults who were given three capsules of “Combipenix” as a single oral administration reached at the peak level about two hours after the administration, then it began to decrease. In tissue levels, activity of the drug was demonstrated almost same concentrations in human nasal polyp and mucous membrane of maxillary antrum. 3. When “Combipenix” was orally administered, as a first choice, to 126 cases of representative infections in ENT field, the clinical effect was excellent or good in 83 cases, fair in 20 cases and ineffective was seen in 10 cases. That is a ratio of effectiveness of 92%. 4. Side effect was detected in 5 cases (4%), but oral administration of the drug was discontinued in only 1 case. In the case, eruption was appeared immediately after oral administration. 5. Thus “Combipenix” can be administered, as a first choice, with its excellent antimicrobial spectrum, even when a causative organism is unknown.